| Drug Name: | Dibekacin (34493-98-6) |
|---|---|
| PubChem ID: | 470999 |
| SMILES: | C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N)N)N |
| InchiKey: | JJCQSGDBDPYCEO-XVZSLQNASA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 451.521 |
| LogP | : | -5.2666 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 13 |
| Hydrogen Bond Donor Count | : | 9 |
| Total Polar Surface Area | : | 247.94 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Aminoglycoside Toxicity | Phospholipase A (P04054) | Dibekacin inhibited both phospholipase A and phospholipase C,which is a possible mechanism of aminoglycoside toxicity. [ ADR Type 1 ] | Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity |
| Aminoglycoside Toxicity | phospholipases C (Q9NQ66) | Dibekacin inhibited both phospholipase A and phospholipase C@which is a possible mechanism of aminoglycoside toxicity. [ ADR Type 1 ] | Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|---|
| Acute Kidney Injury | MetaADEDB |
| Hearing Disorders | MetaADEDB |